Hosoyamada et al. cloned mouse RST cDNA (74% amino-acid identity to human URAT1/SLC22A12; GenBank AB005451) and expressed it in Xenopus oocytes . Urate uptake followed Michaelis-Menten kinetics (Km 1213 ± 222 µM; Vmax 268.8 ± 38.0 pmol/oocyte per h; n = 3), and transport was cis-inhibited by 1 mM probenecid (68.7 ± 9.4% of control), 50 µM benzbromarone (67.9 ± 6.4%), and 10 mM lactate (50.9 ± 9.5%), but not by 1 mM PAH, xanthine, or oxonate. Chloride substitution with gluconate enhanced transport, and pre-injected pyrazinoic acid or L-lactate trans-stimulated uptake — consistent with an anion-exchange mechanism and explaining PZA's antiuricosuric effect as enhanced reabsorption rather than blocked secretion.
Immunohistochemistry with an affinity-purified antibody against RST residues 5–17 stained the brush border/intracellular membranes of proximal tubules. Western blotting detected 70-kD (N-glycosylated, Triton X-100 insoluble brush-border membrane protein) and 62-kD bands. RST mRNA and protein were higher in male than female kidneys — a sex difference with unclear regulatory mechanism.
Strengths: functional, kinetic, pharmacologic, and localization evidence converge; the trans-stimulation design directly tests the exchange model.
Limitations: (1) oocyte heterologous expression may not reproduce native nephron conditions; (2) n = 3 for kinetics is small; (3) the antibody epitope (amino acids 5–17) is short, raising cross-reactivity risk despite oocyte controls; (4) no knockout/knockdown was used to prove physiological necessity — this was addressed only later by mURAT1-deficient mouse models; (5) uricase in mice keeps plasma urate low, so human extrapolation requires caution; (6) female-vs-male differences are reported without mechanistic investigation. Confidence: moderate — conclusions are internally consistent and pharmacologically coherent, but physiological validation awaited genetic models.
Blue bars = reported significant inhibition (mean ± SD from paper); gray bars = no significant inhibition reported.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.